Mounjaro

Mounjaro (tirzepatide) is a prescription-only weekly injection used to manage type 2 diabetes in adults. It belongs to a new class of medications called dual GLP-1 and GIP receptor agonists, which help lower blood sugar, control appetite, and support weight loss.

• Regulates blood sugar levels by stimulating insulin when needed.
• Reduces appetite and slows digestion, leading to weight loss benefits.
• Lowers glucagon production, preventing excessive sugar release by the liver.

• Once-weekly injection, administered under the skin (subcutaneous).
• Available in different strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
• Usually starts at 2.5 mg, with gradual increases as advised by a healthcare professional.

Common side effects (often improve over time):

• Nausea
• Vomiting
• Diarrhoea
• Loss of appetite

link to patient information leaflet

⚠️ Rare but serious side effects:

• Pancreatitis (inflammation of the pancreas)
• Severe allergic reactions
• Thyroid tumours (seen in animal studies; risk in humans is unclear)